Carley's 2026 SD Medical-Repeal Bills

Sen. John Carley’s 2026 SD Medical-Repeal Bills Failed 6–1 / 7–0

Sen. John Carley (R-Piedmont) introduced two cannabis-restriction bills in the 2026 SD legislative session: a potency-cap bill (capping oils at 5% THC, liquid concentrates at 60% THC) rejected 6–1; and SB 181, a medical-program-repeal-trigger bill (90 days after federal rescheduling) rejected 7–0. The Marijuana Policy Project: "Forty states have medical programs. None have repealed their state’s medical cannabis programs."

Legal Disclaimer: This information reflects South Dakota cannabis law as of June 2026 and is for educational purposes only. It is not legal advice. Laws and regulations change — always verify current rules with the South Dakota Department of Health Medical Cannabis Program or a qualified attorney. Cannabis remains illegal under federal law.

Last verified: May 2026

Sen. Carley’s Cannabis Posture

Sen. John Carley (R-Piedmont, Meade County) is the SD Senate’s most consistent cannabis-restrictionist voice. His approach reflects:

Skepticism of voter-approved medical cannabis (IM 26).
Opposition to recreational cannabis re-attempts (IM 27 in 2022, IM 29 in 2024).
Strict view of federal-rescheduling implications for state cannabis policy.
Multi-session pattern of repeal-and-restriction bill introductions.

The 2026 Potency-Cap Proposal

In the 2026 SD legislative session, Sen. Carley introduced legislation that would have:

Capped oils at 5% THC.
Capped liquid concentrates at 60% THC.

The Senate Health and Human Services Committee rejected the bill 6–1. The 5% oil cap would have effectively eliminated most tincture and vape-cart products from the SD market; the 60% concentrate cap would have eliminated most extract products (live resin, distillate, diamonds, etc.).

SB 181 — The Medical-Program Repeal-Trigger Bill

Sen. Carley separately introduced SB 181 in 2026 — a bill that would have repealed the SD medical-cannabis program 90 days after federal cannabis Schedule III rescheduling. The bill was a procedural use of the federal-rescheduling event to dismantle the voter-approved IM 26 program.

The Senate Health and Human Services Committee rejected SB 181 7–0.

The Marijuana Policy Project Commentary

The Marijuana Policy Project (which has substantial SD ballot-and-legislative-process history through Matthew Schweich and SDBML) commented at the time of the 7–0 vote: "Forty states have medical programs. None have repealed their state’s medical cannabis programs."

The MPP commentary captured the structural reality: U.S. medical-cannabis programs, once enacted, are politically durable. Repeal proposals face:

Established patient populations (SD has 18,759 cardholders as of April 2026).
Industry constituencies (70–81 dispensaries, 24–35 cultivators, etc.).
Federal-grant-funded health-care institutions that have integrated cannabis into their patient-care frameworks.
Voter-mandate concerns.

None of the 40 U.S. medical-cannabis programs has been repealed. SD’s 7–0 SB 181 rejection placed it within that broader pattern.

The 2025 Repeal Pattern

Sen. Carley introduced similar repeal-and-restriction bills in the 2025 SD legislative session that the Senate likewise rejected. The recurring pattern reflects his deep cannabis-skepticism and the Senate Health and Human Services Committee’s consistent rejection of repeal-trigger framework.

Why the Senate Rejects Carley’s Bills

Multiple factors explain the consistent committee rejection:

IM 26 voter mandate. The 70%/30% margin remains the strongest medical-cannabis ballot result in U.S. history at the time it was cast. Senators are reluctant to override.
Patient-population growth. 18,759 cardholders represent a meaningful constituency that has integrated medical cannabis into their healthcare.
Industry economic impact. Dispensaries, cultivators, manufacturers employ hundreds and produce tax-revenue and economic activity.
Federal-rescheduling timing. Tying SD repeal to federal rescheduling creates additional uncertainty; senators may prefer status quo to a contingent-trigger framework.
Constitutional concerns. A medical-program repeal could face voter-mandate-override challenges.

The Broader Travis Ismay Repeal Initiative

A separate medical-cannabis repeal initiative tied to activist Travis Ismay has circulated through the AG-statement and signature-gathering processes since 2023. As of May 2026, the initiative has not qualified for any ballot. The repeal initiative would impose direct-democracy reversal of IM 26 if it qualifies and passes — a different procedural pathway than Sen. Carley’s legislative efforts.

The 2027 Outlook

Sen. Carley remains in the SD Senate. Sen. Carley’s 2027 bills are likely to include renewed potency-cap and repeal-trigger proposals. Whether the Senate Health and Human Services Committee continues to reject is the principal forward-looking question for SD cannabis-policy stability.